

BELLICUM PHARMACEUTICALS, INC

Form 4

December 23, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Slawin Kevin M.

(Last) (First) (Middle)

C/O BELLICUM  
PHARMACEUTICALS, INC., 2130  
W. HOLCOMBE BLVD., STE. 800

(Street)

HOUSTON, TX 77030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
BELLICUM  
PHARMACEUTICALS, INC  
[BLCM]

3. Date of Earliest Transaction  
(Month/Day/Year)  
12/23/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
CMO and CTO

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock	12/23/2014		C		17,135	A	(1) 356,370	I	By the Jordana Slawin 2012 Family Trust (2)
Common Stock	12/23/2014		C		64,310	A	(3) 420,680	I	By the Jordana Slawin 2012 Family Trust

Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

Common Stock	12/23/2014	C	41,801	A	<u>(3)</u>	462,481	I	<u>(2)</u> By the Jordana Slawin 2012 Family Trust
Common Stock	12/23/2014	C	16,470	A	<u>(1)</u>	310,587	I	<u>(2)</u> By the Kevin Slawin 2009 Family Trust
Common Stock	12/23/2014	C	56,048	A	<u>(3)</u>	366,635	I	<u>(4)</u> By the Kevin Slawin 2009 Family Trust
Common Stock	12/23/2014	C	36,431	A	<u>(3)</u>	403,066	I	<u>(4)</u> By the Kevin Slawin 2009 Family Trust
Common Stock	12/23/2014	C	16,904	A	<u>(1)</u>	21,805	I	<u>(5)</u> By the 2009 Slawin Family Partnership
Common Stock	12/23/2014	C	65,008	A	<u>(6)</u>	86,813	I	<u>(5)</u> By the 2009 Slawin Family Partnership
Common Stock	12/23/2014	C	15,666	A	<u>(3)</u>	102,479	I	<u>(5)</u> By the 2009 Slawin Family Partnership
Common Stock	12/23/2014	C	10,182	A	<u>(3)</u>	112,661	I	<u>(5)</u> By the 2009 Slawin Family Partnership
Common Stock	12/23/2014	<u>J</u> <sup>(7)</sup>	2,537	A	<u>(3)</u>	115,198	I	<u>(5)</u> By the 2009 Slawin Family Partnership

Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4

Common Stock	12/23/2014	C	22,875	A	(3)	149,639	D
Common Stock	12/23/2014	C	14,868	A	(3)	164,507	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Series A Convertible Preferred Stock	(1)	12/23/2014		C	29,130	(1) (1)	Common Stock 17,135 (8)
Series A Convertible Preferred Stock	(1)	12/23/2014		C	28,000	(1) (1)	Common Stock 16,470 (8)
Series A Convertible Preferred Stock	(1)	12/23/2014		C	28,737	(1) (1)	Common Stock 16,904 (8)
Series B Convertible Participating Preferred Stock	(6)	12/23/2014		C	110,514	(6) (6)	Common Stock 65,008 (8)
Series C Convertible	(3)	12/23/2014		C	38,889	(3) (3)	Common Stock 22,875 (8)

Preferred  
Stock

Series C  
Convertible  
Preferred  
Stock

(3)

12/23/2014

C

109,328

(3)

(3)

Common  
Stock

64,310  
(8)

Series C  
Convertible  
Preferred  
Stock

(3)

12/23/2014

C

95,283

(3)

(3)

Common  
Stock

56,048  
(8)

Series C  
Convertible  
Preferred  
Stock

(3)

12/23/2014

C

26,633

(3)

(3)

Common  
Stock

15,666  
(8)

Series C  
Convertible  
Preferred  
Stock

(3)

12/23/2014

C

25,277

(3)

(3)

Common  
Stock

14,868  
(8)

Series C  
Convertible  
Preferred  
Stock

(3)

12/23/2014

C

71,063

(3)

(3)

Common  
Stock

41,801  
(8)

Series C  
Convertible  
Preferred  
Stock

(3)

12/23/2014

C

61,933

(3)

(3)

Common  
Stock

36,431  
(8)

Series C  
Convertible  
Preferred  
Stock

(3)

12/23/2014

C

17,311

(3)

(3)

Common  
Stock

10,182  
(8)

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director      10% Owner      Officer      Other

Slawin Kevin M.  
C/O BELLICUM PHARMACEUTICALS, INC.  
2130 W. HOLCOMBE BLVD., STE. 800  
HOUSTON, TX 77030

X

CMO  
and  
CTO

## Signatures

/s/ Kevin M.  
Slawin, M.D.

12/23/2014

\_\_Signature of Reporting  
Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The Series A Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.  
The Reporting Person's spouse is trustee of the Jordana Slawin 2012 Family Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- (2) The Series C Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.  
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- (3) The Reporting Person is a managing partner of the 2009 Slawin Family Partnership that owns the reported securities. The Reporting Person has the dispositive power and control over the securities held by such partnership. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- (4) The Series B Convertible Preferred Stock converted into the Issuer's common stock on a 1.7-for-1 basis and had no expiration date.  
On December 4, 2014, the Board of Directors of the Issuer declared a dividend payable to all holders of records of the Series B Convertible Participating Preferred Stock of the Issuer on December 16, 2014, payable in the form of cash or in shares of Common Stock of the Issuer, at the option of each holder. The dividends occurred in connection with the closing of the Issuer's public offering. The Reporting Person elected to receive the shares of Common Stock.
- (5) Reflects 1.7-for-1 reverse stock split which became effective on December 5, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.